Which has preferable earnings and valuation, NTRA or EXEL?

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 21.58 -$208.16M -$1.36 N/A Exelixis $2.32B 6.06 $782.57M $3.18 17.86

Is NTRA or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Exelixis 35.33% 42.17% 31.76%

Does the media favor NTRA or EXEL?

In the previous week, Exelixis had 15 more articles in the media than Natera. MarketBeat recorded 28 mentions for Exelixis and 13 mentions for Natera. Natera's average media sentiment score of 1.04 beat Exelixis' score of 0.30 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 7 Very Negative mention(s) Neutral

Does the media prefer EXEL or RVMD?

In the previous week, Exelixis had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 28 mentions for Exelixis and 16 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.97 beat Exelixis' score of 0.30 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 7 Very Negative mention(s) Neutral Revolution Medicines 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, EXEL or BIIB?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.06 $782.57M $3.18 17.86 Biogen $9.89B 3.23 $1.29B $5.65 38.23

Is EXEL or BIIB more profitable?

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Biogen 8.32% 11.18% 6.88%

Does the media refer more to EXEL or BIIB?

In the previous week, Exelixis had 11 more articles in the media than Biogen. MarketBeat recorded 28 mentions for Exelixis and 17 mentions for Biogen. Biogen's average media sentiment score of 0.95 beat Exelixis' score of 0.30 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 7 Very Negative mention(s) Neutral Biogen 8 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or EXEL?

In the previous week, Exelixis had 20 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 28 mentions for Exelixis and 8 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.85 beat Exelixis' score of 0.30 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 7 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, EXEL or ROIV?

Exelixis has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.06 $782.57M $3.18 17.86 Roivant Sciences $8.26M 3,460.32 -$299.77M -$0.53 N/A

Is EXEL or ROIV more profitable?

Exelixis has a net margin of 35.33% compared to Roivant Sciences' net margin of -3,534.96%. Exelixis' return on equity of 42.17% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media refer more to EXEL or ROIV?

In the previous week, Exelixis had 18 more articles in the media than Roivant Sciences. MarketBeat recorded 28 mentions for Exelixis and 10 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.79 beat Exelixis' score of 0.30 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 7 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exelixis (EXEL) Competitors

$56.78 -0.12 (-0.21%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$56.99 +0.21 (+0.37%)

As of 06:10 AM Eastern

Compare

EXEL vs. NTRA, RVMD, BIIB, ALNY, and ROIV

Should you buy Exelixis stock or one of its competitors? Exelixis's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Natera?

Natera (NASDAQ:NTRA) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	21.58	-$208.16M	-$1.36	N/A
Exelixis	$2.32B	6.06	$782.57M	$3.18	17.86

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Exelixis	35.33%	42.17%	31.76%

Natera presently has a consensus target price of $330.83, indicating a potential downside of 4.20%. Exelixis has a consensus target price of $50.29, indicating a potential downside of 11.44%. Given Natera's stronger consensus rating and higher possible upside, equities analysts clearly believe Natera is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

99.9% of Natera shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 5.1% of Natera shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Exelixis had 15 more articles in the media than Natera. MarketBeat recorded 28 mentions for Exelixis and 13 mentions for Natera. Natera's average media sentiment score of 1.04 beat Exelixis' score of 0.30 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	7 Very Negative mention(s)	Neutral

Natera has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Summary

Natera beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Revolution Medicines?

Exelixis (NASDAQ:EXEL) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Exelixis had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 28 mentions for Exelixis and 16 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.97 beat Exelixis' score of 0.30 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	7 Very Negative mention(s)	Neutral
Revolution Medicines	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.06	$782.57M	$3.18	17.86
Revolution Medicines	$11.58M	3,626.38	-$1.13B	-$8.82	N/A

Exelixis has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Revolution Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Revolution Medicines	N/A	-88.20%	-57.85%

Exelixis currently has a consensus target price of $50.29, indicating a potential downside of 11.44%. Revolution Medicines has a consensus target price of $226.17, indicating a potential upside of 15.44%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summary

Revolution Medicines beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Exelixis (NASDAQ:EXEL) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.06	$782.57M	$3.18	17.86
Biogen	$9.89B	3.23	$1.29B	$5.65	38.23

Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Exelixis presently has a consensus price target of $50.29, indicating a potential downside of 11.44%. Biogen has a consensus price target of $230.14, indicating a potential upside of 6.54%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Biogen	8.32%	11.18%	6.88%

In the previous week, Exelixis had 11 more articles in the media than Biogen. MarketBeat recorded 28 mentions for Exelixis and 17 mentions for Biogen. Biogen's average media sentiment score of 0.95 beat Exelixis' score of 0.30 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	7 Very Negative mention(s)	Neutral
Biogen	8 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Biogen beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Exelixis compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.62	$313.75M	$5.38	44.49
Exelixis	$2.32B	6.06	$782.57M	$3.18	17.86

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Exelixis	35.33%	42.17%	31.76%

Alnylam Pharmaceuticals presently has a consensus target price of $367.20, suggesting a potential upside of 53.41%. Exelixis has a consensus target price of $50.29, suggesting a potential downside of 11.44%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.87
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

In the previous week, Exelixis had 20 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 28 mentions for Exelixis and 8 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.85 beat Exelixis' score of 0.30 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	7 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Exelixis on 11 of the 17 factors compared between the two stocks.

How does Exelixis compare to Roivant Sciences?

Exelixis (NASDAQ:EXEL) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Exelixis presently has a consensus price target of $50.29, suggesting a potential downside of 11.44%. Roivant Sciences has a consensus price target of $41.42, suggesting a potential upside of 4.68%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Exelixis has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exelixis has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.06	$782.57M	$3.18	17.86
Roivant Sciences	$8.26M	3,460.32	-$299.77M	-$0.53	N/A

Exelixis has a net margin of 35.33% compared to Roivant Sciences' net margin of -3,534.96%. Exelixis' return on equity of 42.17% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, Exelixis had 18 more articles in the media than Roivant Sciences. MarketBeat recorded 28 mentions for Exelixis and 10 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.79 beat Exelixis' score of 0.30 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	7 Very Negative mention(s)	Neutral
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exelixis beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.10B	$3.85B	$7.23B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	17.86	14.33	273.89	25.33
Price / Sales	6.06	1,398.16	639.64	87.33
Price / Cash	18.80	108.06	76.40	50.90
Price / Book	7.04	15.13	10.33	6.24
Net Income	$782.57M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-1.13%	-2.50%	-0.80%	-1.20%
1 Month Performance	8.52%	-2.84%	-1.33%	-4.26%
1 Year Performance	40.41%	37.93%	21.15%	5.47%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	2.414 of 5 stars	$56.78 -0.2%	$50.29 -11.4%	+45.1%	$14.10B	$2.32B	17.86	1,077	Analyst Forecast
NTRA Natera	1.9444 of 5 stars	$350.78 +2.6%	$330.83 -5.7%	+97.3%	$50.56B	$2.31B	N/A	6,140	Positive News
RVMD Revolution Medicines	3.2609 of 5 stars	$204.86 -0.1%	$226.17 +10.4%	+338.3%	$43.91B	N/A	N/A	883	Insider Trade
BIIB Biogen	3.4674 of 5 stars	$216.17 -0.5%	$230.14 +6.5%	+50.3%	$31.94B	$9.89B	38.26	7,500	Positive News
ALNY Alnylam Pharmaceuticals	4.1705 of 5 stars	$238.27 -4.7%	$376.67 +58.1%	-48.1%	$31.88B	$3.71B	44.29	2,770

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors

EXEL vs. NTRA, RVMD, BIIB, ALNY, and ROIV

How does Exelixis compare to Natera?

Summary

How does Exelixis compare to Revolution Medicines?

Summary

How does Exelixis compare to Biogen?

Summary

How does Exelixis compare to Alnylam Pharmaceuticals?

Summary

How does Exelixis compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exelixis (EXEL) Competitors

EXEL vs. NTRA, RVMD, BIIB, ALNY, and ROIV

How does Exelixis compare to Natera?

Which has preferable earnings and valuation, NTRA or EXEL?

Is NTRA or EXEL more profitable?

Do analysts prefer NTRA or EXEL?

Do insiders & institutionals have more ownership in NTRA or EXEL?

Does the media favor NTRA or EXEL?

Which has more risk and volatility, NTRA or EXEL?

Summary

How does Exelixis compare to Revolution Medicines?

Does the media prefer EXEL or RVMD?

Which has higher valuation and earnings, EXEL or RVMD?

Which has more volatility and risk, EXEL or RVMD?

Do insiders and institutionals hold more shares of EXEL or RVMD?

Is EXEL or RVMD more profitable?

Do analysts recommend EXEL or RVMD?

Summary

How does Exelixis compare to Biogen?

Which has preferable valuation and earnings, EXEL or BIIB?

Which has more risk and volatility, EXEL or BIIB?

Do analysts recommend EXEL or BIIB?

Is EXEL or BIIB more profitable?

Does the media refer more to EXEL or BIIB?

Do institutionals & insiders believe in EXEL or BIIB?

Summary

How does Exelixis compare to Alnylam Pharmaceuticals?

Which has more risk and volatility, ALNY or EXEL?

Which has stronger valuation and earnings, ALNY or EXEL?

Do institutionals & insiders have more ownership in ALNY or EXEL?

Is ALNY or EXEL more profitable?

Do analysts recommend ALNY or EXEL?

Does the media favor ALNY or EXEL?

Summary

How does Exelixis compare to Roivant Sciences?

Do analysts rate EXEL or ROIV?

Which has more risk & volatility, EXEL or ROIV?

Do institutionals & insiders hold more shares of EXEL or ROIV?

Which has stronger valuation & earnings, EXEL or ROIV?

Is EXEL or ROIV more profitable?

Does the media refer more to EXEL or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools